Arbutus Biopharma (ABUS) Financials

$3.17 -0.04 (-1.25%)

Closing price 05/21/2025 04:00 PM Eastern

Extended Trading

$3.18 +0.01 (+0.44%)

As of 05/21/2025 06:17 PM Eastern

Annual Income Statements for Arbutus Biopharma

This table shows Arbutus Biopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-70	-73	-69
Consolidated Net Income / (Loss)	-70	-73	-69
Net Income / (Loss) Continuing Operations	-70	-73	-69
Total Pre-Tax Income	-70	-73	-65
Total Operating Income	-76	-78	-65
Total Gross Profit	6.17	18	39
Total Revenue	6.17	18	39
Operating Revenue	6.17	18	39
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	82	96	104
Selling, General & Admin Expense	22	22	18
Research & Development Expense	54	74	84
Restructuring Charge	3.72	0.00	-
Other Special Charges / (Income)	2.63	0.07	2.23
Total Other Income / (Expense), net	6.40	5.25	0.44
Interest Expense	0.14	0.46	1.73
Interest & Investment Income	6.59	5.69	2.19
Other Income / (Expense), net	-0.05	0.03	-0.02
Income Tax Expense	0.00	0.00	4.44
Basic Earnings per Share	($0.38)	($0.44)	($0.46)
Weighted Average Basic Shares Outstanding	185.61M	165.96M	150.94M
Diluted Earnings per Share	($0.38)	($0.44)	($0.46)
Weighted Average Diluted Shares Outstanding	185.61M	165.96M	150.94M
Weighted Average Basic & Diluted Shares Outstanding	191.48M	179.49M	162.57M

This table shows Arbutus Biopharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-13	-20	-20	-18	-19	-20	-17	-16	-22	-18
Consolidated Net Income / (Loss)	-13	-20	-20	-18	-19	-20	-17	-16	-22	-18
Net Income / (Loss) Continuing Operations	-13	-20	-20	-18	-19	-20	-17	-16	-22	-18
Total Pre-Tax Income	-13	-20	-20	-18	-19	-20	-17	-16	-22	-18
Total Operating Income	-14	-21	-22	-19	-21	-22	-18	-17	-23	-18
Total Gross Profit	1.57	1.34	1.73	1.53	2.15	4.66	4.65	6.69	6.25	5.95
Total Revenue	1.57	1.34	1.73	1.53	2.15	4.66	4.65	6.69	6.25	5.95
Operating Revenue	1.57	1.34	1.73	1.53	2.15	4.66	4.65	6.69	6.25	5.95
Total Operating Expenses	16	23	23	21	22	26	24	24	29	24
Selling, General & Admin Expense	4.71	4.54	7.55	5.31	5.10	5.84	5.98	5.55	4.25	3.49
Research & Development Expense	8.81	14	16	15	18	20	18	18	23	20
Total Other Income / (Expense), net	1.40	1.72	1.79	1.49	0.80	1.45	1.93	1.07	0.63	0.24
Interest Expense	0.03	0.03	0.03	0.04	0.04	0.05	0.17	0.20	0.31	0.43
Interest & Investment Income	1.46	1.75	1.83	1.55	1.47	1.49	1.46	1.27	0.94	0.69
Other Income / (Expense), net	-0.03	0.01	-0.01	-0.01	-0.62	0.01	0.64	0.00	-0.00	-0.02
Basic Earnings per Share	($0.07)	($0.10)	($0.11)	($0.10)	($0.12)	($0.12)	($0.10)	($0.10)	($0.13)	($0.12)
Weighted Average Basic Shares Outstanding	185.61M	189.00M	188.04M	175.63M	165.96M	167.51M	166.06M	161.64M	150.94M	151.00M
Diluted Earnings per Share	($0.07)	($0.10)	($0.11)	($0.10)	($0.12)	($0.12)	($0.10)	($0.10)	($0.13)	($0.12)
Weighted Average Diluted Shares Outstanding	185.61M	189.00M	188.04M	175.63M	165.96M	167.51M	166.06M	161.64M	150.94M	151.00M
Weighted Average Basic & Diluted Shares Outstanding	191.48M	189.49M	188.78M	188.72M	179.49M	167.70M	167.56M	166.13M	162.57M	156.47M

This table details how cash moves in and out of Arbutus Biopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	10	-4.49	-79
Net Cash From Operating Activities	-65	-86	-35
Net Cash From Continuing Operating Activities	-65	-86	-35
Net Income / (Loss) Continuing Operations	-70	-73	-69
Consolidated Net Income / (Loss)	-70	-73	-69
Depreciation Expense	1.38	1.40	1.43
Amortization Expense	-3.14	-2.20	-0.05
Non-Cash Adjustments To Reconcile Net Income	7.03	5.87	1.25
Changes in Operating Assets and Liabilities, net	-0.20	-18	31
Net Cash From Investing Activities	23	51	-75
Net Cash From Continuing Investing Activities	23	51	-75
Purchase of Property, Plant & Equipment	-0.18	-1.01	-0.51
Purchase of Investments	-142	-81	-130
Sale of Property, Plant & Equipment	0.00	0.02	0.00
Sale and/or Maturity of Investments	165	132	56
Net Cash From Financing Activities	52	31	32
Net Cash From Continuing Financing Activities	52	31	32
Issuance of Common Equity	45	30	21
Other Financing Activities, net	7.48	0.26	0.12
Effect of Exchange Rate Changes	-0.05	0.03	-0.02

This table details how cash moves in and out of Arbutus Biopharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	4.48	-31	20	17	8.75	-9.67	-13	9.80	6.77	-23
Net Cash From Operating Activities	-10	-21	-15	-19	-17	-22	-20	-27	-17	-19
Net Cash From Continuing Operating Activities	-10	-21	-15	-19	-17	-22	-20	-27	-17	-19
Net Income / (Loss) Continuing Operations	-13	-20	-20	-18	-19	-20	-17	-16	-22	-18
Consolidated Net Income / (Loss)	-13	-20	-20	-18	-19	-20	-17	-16	-22	-18
Depreciation Expense	0.33	0.34	0.36	0.36	0.36	0.37	0.34	0.33	0.31	0.34
Amortization Expense	-0.92	-0.98	-0.68	-0.55	-0.62	-0.66	-0.53	-0.39	-0.22	-0.08
Non-Cash Adjustments To Reconcile Net Income	1.15	1.78	2.64	1.46	0.57	1.79	2.37	1.15	-0.26	-0.20
Changes in Operating Assets and Liabilities, net	1.66	-2.16	2.97	-2.68	1.71	-3.18	-4.64	-12	5.12	-1.19
Net Cash From Investing Activities	13	-12	9.83	12	22	10	1.44	17	13	-14
Net Cash From Continuing Investing Activities	13	-12	9.83	12	22	10	1.44	17	13	-14
Purchase of Property, Plant & Equipment	-0.09	-	-0.00	-0.10	-	-0.03	-0.86	-0.12	-0.13	-0.09
Purchase of Investments	-43	-40	-33	-25	-24	-7.09	-29	-20	-13	-33
Sale and/or Maturity of Investments	57	28	42	37	46	18	32	37	26	19
Net Cash From Financing Activities	1.42	1.78	24	24	3.81	1.68	4.74	20	11	9.13
Net Cash From Continuing Financing Activities	1.42	1.78	24	24	3.81	1.68	4.74	20	11	9.13
Issuance of Common Equity	-0.00	0.19	22	22	3.81	1.68	4.74	20	11	9.13
Other Financing Activities, net	1.42	1.59	2.01	2.45	0.00	-	-	0.26	0.00	-
Effect of Exchange Rate Changes	-0.03	0.01	-0.01	-0.01	0.01	0.01	-0.00	0.00	-0.00	-0.02

This table presents Arbutus Biopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	132	144	195
Total Current Assets	127	132	151
Cash & Equivalents	36	26	31
Short-Term Investments	86	100	116
Accounts Receivable	2.41	1.78	1.35
Prepaid Expenses	2.28	4.25	2.87
Plant, Property, & Equipment, net	3.31	4.67	5.07
Total Noncurrent Assets	1.08	7.70	39
Long-Term Investments	0.00	6.28	37
Other Noncurrent Operating Assets	1.08	1.42	1.85
Total Liabilities & Shareholders' Equity	132	144	195
Total Liabilities	34	38	59
Total Current Liabilities	16	22	33
Accounts Payable	7.56	10	16
Current Deferred Revenue	7.57	12	16
Other Current Liabilities	0.48	0.43	0.37
Total Noncurrent Liabilities	19	16	26
Noncurrent Deferred Revenue	2.86	0.00	6.00
Other Noncurrent Operating Liabilities	16	16	20
Total Equity & Noncontrolling Interests	97	106	137
Total Preferred & Common Equity	97	106	137
Total Common Equity	97	106	137
Common Stock	1,492	1,431	1,391
Retained Earnings	-1,347	-1,277	-1,204
Accumulated Other Comprehensive Income / (Loss)	-48	-48	-50

This table presents Arbutus Biopharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	140	160	150	159	177	191	204
Total Current Assets	133	148	136	142	159	153	141
Cash & Equivalents	32	63	43	18	27	41	24
Short-Term Investments	96	79	86	117	125	106	111
Accounts Receivable	1.61	1.77	2.14	2.17	2.61	2.66	1.84
Prepaid Expenses	3.38	4.47	4.49	5.26	3.70	3.46	4.58
Plant, Property, & Equipment, net	3.56	4.06	4.41	5.03	5.37	4.85	5.24
Total Noncurrent Assets	4.11	7.76	10	12	13	34	57
Long-Term Investments	2.96	6.53	8.68	10	11	32	55
Other Noncurrent Operating Assets	1.14	1.24	1.33	1.51	1.60	1.73	1.99
Total Liabilities & Shareholders' Equity	140	160	150	159	177	191	204
Total Liabilities	34	38	36	39	42	47	58
Total Current Liabilities	19	23	20	22	25	25	28
Accounts Payable	7.54	11	8.25	9.81	8.81	9.65	12
Current Deferred Revenue	11	11	12	12	15	15	15
Other Current Liabilities	0.47	0.45	0.50	0.41	0.40	0.45	0.36
Total Noncurrent Liabilities	15	15	15	17	18	22	31
Other Noncurrent Operating Liabilities	15	15	15	17	18	19	20
Total Equity & Noncontrolling Interests	107	122	115	119	135	144	146
Total Preferred & Common Equity	107	122	115	119	135	144	146
Total Common Equity	107	122	115	119	135	144	146
Common Stock	1,489	1,485	1,458	1,426	1,421	1,414	1,378
Retained Earnings	-1,334	-1,314	-1,295	-1,257	-1,237	-1,220	-1,182
Accumulated Other Comprehensive Income / (Loss)	-48	-48	-48	-49	-49	-50	-51

This table displays calculated financial ratios and metrics derived from Arbutus Biopharma's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	-65.98%	-53.51%	255.11%
EBITDA Growth	0.95%	-23.03%	9.41%
EBIT Growth	2.19%	-19.24%	10.93%
NOPAT Growth	2.28%	-19.32%	10.97%
Net Income Growth	4.02%	-4.89%	8.91%
EPS Growth	13.64%	4.35%	44.58%
Operating Cash Flow Growth	24.54%	-143.06%	47.65%
Free Cash Flow Firm Growth	28.21%	-279.87%	61.01%
Invested Capital Growth	3.85%	44.61%	-119.90%
Revenue Q/Q Growth	-8.47%	-18.43%	8.45%
EBITDA Q/Q Growth	8.30%	1.07%	-3.83%
EBIT Q/Q Growth	8.84%	1.51%	-2.79%
NOPAT Q/Q Growth	8.20%	2.27%	-2.77%
Net Income Q/Q Growth	8.84%	3.47%	-0.89%
EPS Q/Q Growth	11.63%	2.22%	4.17%
Operating Cash Flow Q/Q Growth	9.71%	-0.35%	6.89%
Free Cash Flow Firm Q/Q Growth	8.76%	-0.78%	8.19%
Invested Capital Q/Q Growth	-5.82%	-3.67%	-6.24%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-1,265.97%	-434.76%	-164.29%
Operating Margin	-1,236.74%	-430.53%	-167.75%
EBIT Margin	-1,237.53%	-430.40%	-167.81%
Profit (Net Income) Margin	-1,133.04%	-401.57%	-178.01%
Tax Burden Percent	100.00%	100.00%	106.84%
Interest Burden Percent	91.56%	93.30%	99.29%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-68.76%	-59.99%	-45.35%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-55.32%	-45.95%	-32.75%
Return on Assets (ROA)	-50.65%	-42.88%	-34.74%
Return on Common Equity (ROCE)	-68.76%	-59.99%	-45.35%
Return on Equity Simple (ROE_SIMPLE)	-71.81%	-68.71%	-50.75%
Net Operating Profit after Tax (NOPAT)	-53	-55	-46
NOPAT Margin	-865.72%	-301.37%	-117.43%
Net Nonoperating Expense Percent (NNEP)	-12.94%	-11.48%	-12.60%
Return On Investment Capital (ROIC_SIMPLE)	-54.87%	-51.57%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	358.26%	123.89%	45.71%
R&D to Revenue	875.66%	406.26%	216.33%
Operating Expenses to Revenue	1,336.74%	530.53%	267.75%
Earnings before Interest and Taxes (EBIT)	-76	-78	-65
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-78	-79	-64
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	6.36	3.95	2.66
Price to Tangible Book Value (P/TBV)	6.36	3.95	2.66
Price to Revenue (P/Rev)	100.41	23.11	9.34
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	80.54	15.82	4.62
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.25	-1.30	-1.23
Leverage Ratio	1.36	1.40	1.31
Compound Leverage Factor	1.24	1.31	1.30
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	-4.34	-6.57	-5.07
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	8.15	5.87	4.60
Quick Ratio	8.01	5.68	4.51
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-54	-76	-20
Operating Cash Flow to CapEx	-35,631.87%	-8,697.98%	-6,905.47%
Free Cash Flow to Firm to Interest Expense	-397.34	-165.20	-11.57
Operating Cash Flow to Interest Expense	-473.36	-187.22	-20.48
Operating Cash Flow Less CapEx to Interest Expense	-474.69	-189.38	-20.78
Efficiency Ratios	-	-	-
Asset Turnover	0.04	0.11	0.20
Accounts Receivable Turnover	2.95	11.60	34.67
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	1.55	3.72	7.06
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	123.77	31.47	10.53
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	123.77	31.47	10.53
Capital & Investment Metrics	-	-	-
Invested Capital	-25	-26	-47
Invested Capital Turnover	-0.24	-0.49	-1.13
Increase / (Decrease) in Invested Capital	1.01	21	-26
Enterprise Value (EV)	497	287	180
Market Capitalization	620	419	365
Book Value per Share	$0.51	$0.63	$0.87
Tangible Book Value per Share	$0.51	$0.63	$0.87
Total Capital	97	106	137
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-123	-132	-184
Capital Expenditures (CapEx)	0.18	0.99	0.51
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-11	-16	-29
Debt-free Net Working Capital (DFNWC)	112	110	118
Net Working Capital (NWC)	112	110	118
Net Nonoperating Expense (NNE)	16	18	24
Net Nonoperating Obligations (NNO)	-123	-132	-184
Total Depreciation and Amortization (D&A)	-1.76	-0.79	1.37
Debt-free, Cash-free Net Working Capital to Revenue	-177.04%	-90.75%	-73.38%
Debt-free Net Working Capital to Revenue	1,810.05%	603.83%	303.14%
Net Working Capital to Revenue	1,810.05%	603.83%	303.14%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.38)	($0.44)	($0.46)
Adjusted Weighted Average Basic Shares Outstanding	185.61M	165.96M	150.94M
Adjusted Diluted Earnings per Share	($0.38)	($0.44)	($0.46)
Adjusted Weighted Average Diluted Shares Outstanding	185.61M	165.96M	150.94M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	191.48M	179.49M	162.57M
Normalized Net Operating Profit after Tax (NOPAT)	-49	-55	-44
Normalized NOPAT Margin	-793.74%	-301.11%	-113.42%
Pre Tax Income Margin	-1,133.04%	-401.57%	-166.62%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-557.43	-170.10	-37.94
NOPAT to Interest Expense	-389.95	-119.11	-26.55
EBIT Less CapEx to Interest Expense	-558.76	-172.26	-38.23
NOPAT Less CapEx to Interest Expense	-391.28	-121.26	-26.84
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	15.80%

This table displays calculated financial ratios and metrics derived from Arbutus Biopharma's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-26.62%	-71.25%	-62.89%	-77.09%	-65.65%	-21.74%	-67.34%	-46.85%	94.79%	78.20%
EBITDA Growth	32.70%	-1.10%	-22.13%	-12.11%	3.80%	-24.31%	-31.52%	-67.69%	-11.76%	0.60%
EBIT Growth	34.64%	0.54%	-21.65%	-11.30%	5.30%	-20.86%	-25.82%	-58.64%	-8.54%	3.21%
NOPAT Growth	32.84%	0.55%	-17.39%	-11.20%	8.04%	-21.04%	-30.31%	-58.68%	-8.49%	3.24%
Net Income Growth	35.11%	1.93%	-15.81%	-9.40%	11.95%	-14.44%	-20.45%	-3.64%	-2.87%	8.30%
EPS Growth	41.67%	16.67%	-10.00%	0.00%	7.69%	0.00%	0.00%	9.09%	13.33%	50.00%
Operating Cash Flow Growth	40.35%	4.81%	25.84%	29.32%	-1.78%	-16.54%	3.62%	-232.41%	13.34%	-16.56%
Free Cash Flow Firm Growth	69.83%	52.08%	43.24%	25.82%	-454.49%	-431.54%	-283.58%	-210.11%	170.42%	186.15%
Invested Capital Growth	3.85%	5.81%	9.67%	32.72%	44.61%	43.23%	39.28%	38.15%	-119.90%	-104.79%
Revenue Q/Q Growth	17.55%	-22.42%	12.66%	-28.58%	-53.95%	0.15%	-30.45%	7.08%	4.92%	-58.21%
EBITDA Q/Q Growth	34.08%	-0.78%	-11.94%	6.76%	0.97%	-21.74%	-2.75%	22.34%	-27.96%	-28.81%
EBIT Q/Q Growth	34.84%	0.72%	-11.43%	6.55%	0.85%	-21.43%	-1.95%	22.85%	-26.55%	-26.41%
NOPAT Q/Q Growth	35.01%	0.66%	-11.47%	6.67%	3.76%	-17.26%	-5.58%	22.82%	-26.67%	-26.24%
Net Income Q/Q Growth	36.44%	0.40%	-10.75%	7.44%	3.94%	-17.61%	-4.62%	25.50%	-24.85%	-23.78%
EPS Q/Q Growth	30.00%	9.09%	-10.00%	16.67%	0.00%	-20.00%	0.00%	23.08%	-8.33%	-20.00%
Operating Cash Flow Q/Q Growth	50.26%	-42.97%	24.83%	-11.58%	20.62%	-11.38%	28.36%	-60.69%	9.11%	7.89%
Free Cash Flow Firm Q/Q Growth	34.67%	7.92%	28.06%	30.27%	-3.75%	-9.07%	5.99%	-433.21%	-2.97%	-39.61%
Invested Capital Q/Q Growth	-5.82%	8.41%	-11.94%	11.38%	-3.67%	12.16%	16.63%	27.03%	-6.24%	6.04%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-924.78%	-1,649.14%	-1,269.47%	-1,277.68%	-1,008.35%	-468.89%	-385.72%	-261.10%	-360.02%	-295.19%
Operating Margin	-885.20%	-1,601.19%	-1,250.46%	-1,263.90%	-967.23%	-462.82%	-395.29%	-260.40%	-361.28%	-299.24%
EBIT Margin	-887.29%	-1,600.82%	-1,250.93%	-1,264.75%	-996.22%	-462.69%	-381.60%	-260.34%	-361.35%	-299.60%
Profit (Net Income) Margin	-796.19%	-1,472.52%	-1,146.93%	-1,166.78%	-900.33%	-431.60%	-367.53%	-244.34%	-351.19%	-295.14%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	89.73%	91.99%	91.69%	92.25%	90.37%	93.28%	96.32%	93.85%	97.19%	98.51%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-68.76%	-67.81%	-59.96%	-57.54%	-59.99%	-56.99%	-50.68%	-45.22%	-45.35%	-49.95%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-39.66%	-72.17%	-74.72%	-96.18%	-106.37%	-56.79%	-45.74%	-40.29%	-70.51%	-58.36%
Return on Assets (ROA)	-35.59%	-66.39%	-68.51%	-88.73%	-96.13%	-52.97%	-44.06%	-37.81%	-68.53%	-57.50%
Return on Common Equity (ROCE)	-68.76%	-67.81%	-59.96%	-57.54%	-59.99%	-56.99%	-50.68%	-45.22%	-45.35%	-49.95%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-71.76%	-62.95%	-64.89%	0.00%	-63.24%	-54.15%	-48.66%	0.00%	-47.31%
Net Operating Profit after Tax (NOPAT)	-9.75	-15	-15	-14	-15	-15	-13	-12	-16	-12
NOPAT Margin	-619.64%	-1,120.84%	-875.32%	-884.73%	-677.06%	-323.97%	-276.70%	-182.28%	-252.90%	-209.47%
Net Nonoperating Expense Percent (NNEP)	-2.18%	-3.42%	-3.00%	-2.73%	-3.03%	-2.99%	-2.32%	-2.07%	-3.27%	-2.98%
Return On Investment Capital (ROIC_SIMPLE)	-10.02%	-	-	-	-13.70%	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	299.36%	338.84%	437.25%	346.74%	237.81%	125.42%	128.57%	83.03%	68.04%	58.69%
R&D to Revenue	559.72%	1,065.94%	900.98%	1,005.42%	818.83%	433.00%	380.39%	273.29%	367.48%	336.95%
Operating Expenses to Revenue	985.20%	1,701.19%	1,350.46%	1,363.90%	1,037.58%	562.82%	508.97%	360.40%	461.28%	399.24%
Earnings before Interest and Taxes (EBIT)	-14	-21	-22	-19	-21	-22	-18	-17	-23	-18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-15	-22	-22	-20	-22	-22	-18	-17	-22	-18
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.36	6.80	4.76	4.04	3.95	2.85	2.84	3.42	2.66	1.97
Price to Tangible Book Value (P/TBV)	6.36	6.80	4.76	4.04	3.95	2.85	2.84	3.42	2.66	1.97
Price to Revenue (P/Rev)	100.41	107.80	57.96	35.66	23.11	15.29	16.24	14.87	9.34	7.96
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	80.54	88.41	43.20	25.04	15.82	8.79	9.29	9.48	4.62	2.68
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.25	-1.22	-1.21	-1.22	-1.30	-1.26	-1.27	-1.29	-1.23	-1.24
Leverage Ratio	1.36	1.32	1.31	1.32	1.40	1.37	1.36	1.38	1.31	1.34
Compound Leverage Factor	1.22	1.22	1.20	1.22	1.26	1.28	1.31	1.30	1.27	1.32
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-2.77	0.22	-1.63	-3.68	-5.28	-5.31	-3.64	-2.01	-4.34	-4.61
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	8.15	7.02	6.56	6.69	5.87	6.34	6.47	6.08	4.60	5.13
Quick Ratio	8.01	6.84	6.36	6.47	5.68	6.11	6.32	5.94	4.51	4.96
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-11	-16	-18	-25	-36	-34	-32	-34	10	10
Operating Cash Flow to CapEx	-11,994.19%	0.00%	-1,450,400.00%	-20,310.53%	0.00%	-68,075.00%	-2,276.95%	-23,334.19%	-11,032.47%	-20,540.66%
Free Cash Flow to Firm to Interest Expense	-358.84	-568.24	-526.39	-565.39	-810.86	-747.58	-184.38	-169.37	32.57	24.18
Operating Cash Flow to Interest Expense	-343.83	-715.03	-426.59	-438.52	-393.00	-473.57	-114.38	-137.88	-54.98	-43.57
Operating Cash Flow Less CapEx to Interest Expense	-346.70	-715.03	-426.62	-440.68	-393.00	-474.26	-119.40	-138.47	-55.48	-43.78
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.04	0.05	0.06	0.08	0.11	0.12	0.12	0.15	0.20	0.19
Accounts Receivable Turnover	2.95	3.57	4.59	5.41	11.60	11.10	10.27	16.66	34.67	20.55
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	1.55	1.57	2.13	2.80	3.72	4.33	4.33	6.30	7.06	6.21
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	123.77	102.29	79.47	67.50	31.47	32.87	35.55	21.91	10.53	17.76
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	123.77	102.29	79.47	67.50	31.47	32.87	35.55	21.91	10.53	17.76
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-25	-24	-26	-23	-26	-25	-29	-35	-47	-45
Invested Capital Turnover	-0.24	-0.27	-0.37	-0.45	-0.49	-0.64	-0.62	-0.73	-1.13	-1.08
Increase / (Decrease) in Invested Capital	1.01	1.47	2.79	11	21	19	19	21	-26	-23
Enterprise Value (EV)	497	596	435	325	287	195	219	314	180	96
Market Capitalization	620	727	583	463	419	340	382	493	365	286
Book Value per Share	$0.51	$0.57	$0.65	$0.64	$0.63	$0.71	$0.81	$0.89	$0.87	$0.97
Tangible Book Value per Share	$0.51	$0.57	$0.65	$0.64	$0.63	$0.71	$0.81	$0.89	$0.87	$0.97
Total Capital	97	107	122	115	106	119	135	144	137	146
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-123	-131	-149	-138	-132	-145	-164	-179	-184	-190
Capital Expenditures (CapEx)	0.09	0.00	0.00	0.10	0.00	0.03	0.86	0.12	0.15	0.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-11	-14	-16	-14	-16	-15	-18	-19	-29	-21
Debt-free Net Working Capital (DFNWC)	112	114	126	116	110	119	134	128	118	114
Net Working Capital (NWC)	112	114	126	116	110	119	134	128	118	114
Net Nonoperating Expense (NNE)	2.78	4.71	4.69	4.32	4.79	5.01	4.22	4.15	6.14	5.10
Net Nonoperating Obligations (NNO)	-123	-131	-149	-138	-132	-145	-164	-179	-184	-190
Total Depreciation and Amortization (D&A)	-0.59	-0.65	-0.32	-0.20	-0.26	-0.29	-0.19	-0.05	0.08	0.26
Debt-free, Cash-free Net Working Capital to Revenue	-177.04%	-206.76%	-162.62%	-105.22%	-90.75%	-66.98%	-77.39%	-57.44%	-73.38%	-58.61%
Debt-free Net Working Capital to Revenue	1,810.05%	1,688.73%	1,248.63%	890.00%	603.83%	536.32%	570.52%	385.51%	303.14%	315.81%
Net Working Capital to Revenue	1,810.05%	1,688.73%	1,248.63%	890.00%	603.83%	536.32%	570.52%	385.51%	303.14%	315.81%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.07)	($0.10)	($0.11)	($0.10)	($0.12)	($0.12)	($0.10)	($0.10)	($0.13)	($0.12)
Adjusted Weighted Average Basic Shares Outstanding	185.61M	189.00M	188.04M	175.63M	165.96M	167.51M	166.06M	161.64M	150.94M	151.00M
Adjusted Diluted Earnings per Share	($0.07)	($0.10)	($0.11)	($0.10)	($0.12)	($0.12)	($0.10)	($0.10)	($0.13)	($0.12)
Adjusted Weighted Average Diluted Shares Outstanding	185.61M	189.00M	188.04M	175.63M	165.96M	167.51M	166.06M	161.64M	150.94M	151.00M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	191.48M	189.49M	188.78M	188.72M	179.49M	167.70M	167.56M	166.13M	162.57M	156.47M
Normalized Net Operating Profit after Tax (NOPAT)	-9.75	-12	-15	-14	-15	-15	-13	-12	-16	-12
Normalized NOPAT Margin	-619.64%	-931.33%	-875.32%	-884.73%	-677.06%	-323.97%	-276.70%	-182.28%	-252.90%	-209.47%
Pre Tax Income Margin	-796.19%	-1,472.52%	-1,146.93%	-1,166.78%	-900.33%	-431.60%	-367.53%	-244.34%	-351.19%	-295.14%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-465.53	-739.14	-635.03	-440.36	-485.66	-468.52	-103.79	-87.92	-73.03	-41.57
NOPAT to Interest Expense	-325.10	-517.52	-444.36	-308.05	-330.07	-328.06	-75.26	-61.56	-51.11	-29.06
EBIT Less CapEx to Interest Expense	-468.40	-739.14	-635.06	-442.52	-485.66	-469.22	-108.81	-88.52	-73.53	-41.78
NOPAT Less CapEx to Interest Expense	-327.97	-517.52	-444.39	-310.21	-330.07	-328.75	-80.28	-62.15	-51.61	-29.27
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	15.80%	0.00%

Frequently Asked Questions About Arbutus Biopharma's Financials

When does Arbutus Biopharma's fiscal year end?

According to the most recent income statement we have on file, Arbutus Biopharma's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Arbutus Biopharma's net income changed over the last 2 years?

Arbutus Biopharma's net income were at -$69.92 million at the end of 2024, a 4.0% decrease from 2023, and a 0.7% increase since 2022. See Arbutus Biopharma's forecast for analyst expectations on what’s next for the company.

What is Arbutus Biopharma's operating income?

Arbutus Biopharma's total operating income in 2024 was -$76.32 million, based on the following breakdown:

Total Gross Profit: $6.17 million
Total Operating Expenses: $82.49 million

How has Arbutus Biopharma revenue changed over the last 2 years?

Over the last 2 years, Arbutus Biopharma's total revenue changed from $39.02 million in 2022 to $6.17 million in 2024, a change of -84.2%.

How much debt does Arbutus Biopharma have?

Arbutus Biopharma's total liabilities were at $34.34 million at the end of 2024, a 10.5% decrease from 2023, and a 41.4% decrease since 2022.

How much cash does Arbutus Biopharma have?

In the past 2 years, Arbutus Biopharma's cash and equivalents has ranged from $26.29 million in 2023 to $36.33 million in 2024, and is currently $36.33 million as of their latest financial filing in 2024.

How has Arbutus Biopharma's book value per share changed over the last 2 years?

Over the last 2 years, Arbutus Biopharma's book value per share changed from 0.87 in 2022 to 0.51 in 2024, a change of -41.3%.

Related Companies

This page (NASDAQ:ABUS) was last updated on 5/22/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arbutus Biopharma (ABUS) Financials

Frequently Asked Questions About Arbutus Biopharma's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arbutus Biopharma (ABUS) Financials

Annual Income Statements for Arbutus Biopharma

Quarterly Income Statements for Arbutus Biopharma

Annual Cash Flow Statements for Arbutus Biopharma

Quarterly Cash Flow Statements for Arbutus Biopharma

Annual Balance Sheets for Arbutus Biopharma

Quarterly Balance Sheets for Arbutus Biopharma

Annual Metrics And Ratios for Arbutus Biopharma

Quarterly Metrics And Ratios for Arbutus Biopharma

Frequently Asked Questions About Arbutus Biopharma's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools